Who we are
Disruptive Pharma is a Swedish pharmaceutical technology company developing and commercializing Formulite®, a patented and clinically evaluated platform technology for oral drug formulation and drug product development. Formulite® is designed to stabilize drug compounds in an amorphous state, improving solubility and oral bioavailability and creating new opportunities to develop and optimize oral drug products. The company is listed on Nasdaq First North Growth Market Stockholm.
The Formulite® platform addresses formulation challenges that can limit both drug performance and commercial potential. By improving key formulation properties, Formulite® can support the development of novel medicines, improve existing treatments and enable smaller, simpler and more convenient oral dosage forms for patients.
In 2025, the first clinical study of a Formulite®-based formulation was completed in healthy volunteers, demonstrating that Formulite® can be used as a functional drug carrier in humans and providing an important foundation for further partnering and development.
Business model
Disruptive Pharma’s strategy focuses on collaborations with pharmaceutical and biotechnology companies and strategic development and manufacturing partners.
Collaborations can progress from feasibility and formulation development through preclinical and clinical development, scale-up, licensing and commercialization.
Technology born from world-class nanoscience
Disruptive Pharma is rooted in nanoscience research conducted at Uppsala University, where work led by Professor Maria Strömme resulted in the discovery of a novel nanostructured, amorphous magnesium carbonate material (MMC).
A first patent application was filed in 2012, forming the basis for Disruptive Materials. To fully focus on pharmaceutical applications, Disruptive Pharma was established in 2021 as a spin-out, dedicated to developing and commercializing the Formulite® technology platform. Since then, Formulite® has evolved from a material technology into a bioavailability platform, evaluated across a broad range of drug compounds and formulations, supported by preclinical studies and, most recently, a first clinical study in humans. This clinical validation marks an important milestone in the continued development and commercialization of the platform.